Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-carotene + ascorbic acid + tocopherol
- Development stage
- Unknown
- Lead developer
- Ibn Sina Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Race is an oral antioxidant combination tablet developed and marketed by Ibn Sina Pharmaceuticals. Each film-coated tablet contains beta-carotene (6 mg), ascorbic acid (vitamin C, 200 mg), and tocopherol (vitamin E, 50 mg). This combination of vitamins acts synergistically to scavenge free radicals, reduce oxidative stress, and protect cell membranes from lipid peroxidation. It is indicated for reducing the risk of cardiovascular diseases, cataracts, and age-related degenerative conditions, as well as supporting immune function.
- Brand names
- Race
- Other names
- beta-carotene + vitamin c + vitamin ebetacarotene + ascorbic acid + tocopherolbetacarotene + vitamin c + vitamin e
Beyond the preview
Go deeper on beta-carotene + ascorbic acid + tocopherol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta-carotene + ascorbic acid + tocopherol.